Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from ANGLE plc ( (GB:CLBX) ) is now available.
CelLBxHealth plc announced that all resolutions were approved at their General Meeting, paving the way for significant changes, including the transition of Peter Collins from Interim CEO to CEO and the anticipated appointment of new board members in January 2026. The company is also undergoing a share capital reorganization and has applied for new shares to be admitted to trading on AIM, which is expected to enhance its market presence and drive sustainable growth.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
Spark’s Take on GB:CLBX Stock
According to Spark, TipRanks’ AI Analyst, GB:CLBX is a Neutral.
The overall stock score reflects significant financial challenges and bearish technical indicators, which are the most impactful factors. While recent corporate events and earnings call achievements provide some positive outlook, the financial and valuation concerns weigh heavily on the score.
To see Spark’s full report on GB:CLBX stock, click here.
More about ANGLE plc
CelLBxHealth plc is a precision circulating tumour cell (CTC) intelligence company that specializes in innovative CTC solutions for research, drug development, and clinical oncology. The company offers the Parsortix® platform, which harvests CTCs from blood for comprehensive analysis, and focuses on product sales, laboratory services, and lab-developed tests.
Average Trading Volume: 2,793,404
Technical Sentiment Signal: Sell
Current Market Cap: £3.87M
Find detailed analytics on CLBX stock on TipRanks’ Stock Analysis page.